NEW YORK (GenomeWeb News) – Epigenomics and Pronto Diagnostics today announced a distribution agreement for Epigenomics' Epi proColon colorectal cancer test in Israel.
Pronto, based in Tel Aviv, Israel plans to begin marketing the test in Israel next month.
The test is based on Epigenomics' proprietary biomarker, Septin9, and is CE marked for sale in Germany, Austria, Switzerland. In a statement, Epigenomics, based in Berlin, said that the Epi proColon test is the firm CE-marked molecular diagnostic test for the early detection of colorectal cancer in blood.
The company said it plans to make the test broadly available, outside its home market through a mixture of direct commercialization and a distributor network.
Terms of the deal were not disclosed.